首页 > 最新文献

Pulmonary Medicine最新文献

英文 中文
Warfarin Use Is Associated with Increased Mortality at One Year in Patients with Idiopathic Pulmonary Fibrosis. 使用华法林与特发性肺纤维化患者一年内死亡率增加相关
IF 4.3 Q1 Medicine Pub Date : 2021-11-25 eCollection Date: 2021-01-01 DOI: 10.1155/2021/3432362
Syeda Fatima Naqvi, Amir Humza Sohail, Dhairya A Lakhani, James Maurer, Sarah Sofka, Yousaf B Hadi

Objectives: We studied the safety and efficacy of warfarin compared to direct acting oral anticoagulant use in patients with IPF.

Methods: We conducted a retrospective cohort study of all patients with IPF who were prescribed warfarin or direct acting oral anticoagulants (DOACs) for cardiac or thromboembolic indications and followed at our institute for their care. Univariate tests and multivariable logistic regression analyses were used for assessing association of variables with outcomes.

Results: A total of 73 patients were included in the study with 28 and 45 patients in the warfarin and DOAC groups, respectively. Univariable analysis revealed a significant difference in mortality in one year between warfarin and DOAC groups (7/28 vs. 3/45, p value 0.027). Significantly more patients in the warfarin group suffered an exacerbation that required hospitalization within one year (9/28 vs. 5/45, p value 0.026). Multivariate logistic regression analysis showed that anticoagulation with warfarin was independently associated with mortality at one-year follow-up (OR: 77.4, 95% CI: 5.94-409.3, p value: 0.007).

Conclusion: In our study of patients with IPF requiring anticoagulants, we noted statistically significant higher mortality with warfarin anticoagulation when compared to DOAC use. Further larger prospective studies are needed to confirm these findings.

目的:研究华法林与直接口服抗凝剂在IPF患者中的安全性和有效性。方法:我们对所有因心脏或血栓栓塞适应症而服用华法林或直接作用口服抗凝剂(DOACs)的IPF患者进行了回顾性队列研究,并在我们的研究所进行了随访。单变量检验和多变量逻辑回归分析用于评估变量与结果的关联。结果:共纳入73例患者,华法林组28例,DOAC组45例。单变量分析显示华法林组和DOAC组1年死亡率有显著差异(7/28 vs. 3/45, p值0.027)。华法林组患者在一年内出现加重并需要住院治疗的患者明显更多(9/28比5/45,p值0.026)。多因素logistic回归分析显示,华法林抗凝与1年随访死亡率独立相关(OR: 77.4, 95% CI: 5.94-409.3, p值:0.007)。结论:在我们对需要抗凝治疗的IPF患者的研究中,我们注意到与使用DOAC相比,华法林抗凝治疗的死亡率有统计学意义。需要进一步更大规模的前瞻性研究来证实这些发现。
{"title":"Warfarin Use Is Associated with Increased Mortality at One Year in Patients with Idiopathic Pulmonary Fibrosis.","authors":"Syeda Fatima Naqvi,&nbsp;Amir Humza Sohail,&nbsp;Dhairya A Lakhani,&nbsp;James Maurer,&nbsp;Sarah Sofka,&nbsp;Yousaf B Hadi","doi":"10.1155/2021/3432362","DOIUrl":"https://doi.org/10.1155/2021/3432362","url":null,"abstract":"<p><strong>Objectives: </strong>We studied the safety and efficacy of warfarin compared to direct acting oral anticoagulant use in patients with IPF.</p><p><strong>Methods: </strong>We conducted a retrospective cohort study of all patients with IPF who were prescribed warfarin or direct acting oral anticoagulants (DOACs) for cardiac or thromboembolic indications and followed at our institute for their care. Univariate tests and multivariable logistic regression analyses were used for assessing association of variables with outcomes.</p><p><strong>Results: </strong>A total of 73 patients were included in the study with 28 and 45 patients in the warfarin and DOAC groups, respectively. Univariable analysis revealed a significant difference in mortality in one year between warfarin and DOAC groups (7/28 vs. 3/45, <i>p</i> value 0.027). Significantly more patients in the warfarin group suffered an exacerbation that required hospitalization within one year (9/28 vs. 5/45, <i>p</i> value 0.026). Multivariate logistic regression analysis showed that anticoagulation with warfarin was independently associated with mortality at one-year follow-up (OR: 77.4, 95% CI: 5.94-409.3, <i>p</i> value: 0.007).</p><p><strong>Conclusion: </strong>In our study of patients with IPF requiring anticoagulants, we noted statistically significant higher mortality with warfarin anticoagulation when compared to DOAC use. Further larger prospective studies are needed to confirm these findings.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8639231/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39695822","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Periodontal Diseases: Major Exacerbators of Pulmonary Diseases? 牙周病:肺部疾病的主要加重因素?
IF 4.3 Q1 Medicine Pub Date : 2021-11-02 eCollection Date: 2021-01-01 DOI: 10.1155/2021/4712406
Bakey Kouanda, Zeeshan Sattar, Patrick Geraghty

Periodontal diseases are a range of polymicrobial infectious disorders, such as gingivitis and periodontitis, which affect tooth-supporting tissues and are linked to playing a role in the exacerbation of several pulmonary diseases. Pulmonary diseases, such as pneumonia, chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, COVID-19, and bronchiectasis, significantly contribute to poor quality of life and mortality. The association between periodontal disease and pulmonary outcomes is an important topic and requires further attention. Numerous resident microorganisms coexist in the oral cavity and lungs. However, changes in the normal microflora due to oral disease, old age, lifestyle habits, or dental intervention may contribute to altered aspiration of oral periodontopathic bacteria into the lungs and changing inflammatory responses. Equally, periodontal diseases are associated with the longitudinal decline in spirometry lung volume. Several studies suggest a possible beneficial effect of periodontal therapy in improving lung function with a decreased frequency of exacerbations and reduced risk of adverse respiratory events and morbidity. Here, we review the current literature outlining the link between the oral cavity and pulmonary outcomes and focus on the microflora of the oral cavity, environmental and genetic factors, and preexisting conditions that can impact oral and pulmonary outcomes.

牙周病是一系列多微生物感染性疾病,如牙龈炎和牙周炎,它们会影响牙齿支撑组织,并在几种肺部疾病的恶化中发挥作用。肺炎、慢性阻塞性肺病(COPD)、哮喘、结核病、新冠肺炎和支气管扩张等肺部疾病严重导致生活质量差和死亡率。牙周病与肺部预后之间的关系是一个重要的课题,需要进一步关注。口腔和肺部共存着许多常驻微生物。然而,由于口腔疾病、老年、生活习惯或牙科干预导致的正常菌群的变化可能会导致口腔牙周病细菌进入肺部的吸入改变和炎症反应的改变。同样,牙周病与肺活量测定肺容量的纵向下降有关。几项研究表明,牙周治疗在改善肺功能方面可能具有有益效果,可以降低恶化频率,降低不良呼吸事件和发病率的风险。在这里,我们回顾了目前概述口腔和肺部结果之间联系的文献,并重点关注口腔的微生物群落、环境和遗传因素,以及可能影响口腔和肺部结局的先前存在的条件。
{"title":"Periodontal Diseases: Major Exacerbators of Pulmonary Diseases?","authors":"Bakey Kouanda,&nbsp;Zeeshan Sattar,&nbsp;Patrick Geraghty","doi":"10.1155/2021/4712406","DOIUrl":"10.1155/2021/4712406","url":null,"abstract":"<p><p>Periodontal diseases are a range of polymicrobial infectious disorders, such as gingivitis and periodontitis, which affect tooth-supporting tissues and are linked to playing a role in the exacerbation of several pulmonary diseases. Pulmonary diseases, such as pneumonia, chronic obstructive pulmonary disease (COPD), asthma, tuberculosis, COVID-19, and bronchiectasis, significantly contribute to poor quality of life and mortality. The association between periodontal disease and pulmonary outcomes is an important topic and requires further attention. Numerous resident microorganisms coexist in the oral cavity and lungs. However, changes in the normal microflora due to oral disease, old age, lifestyle habits, or dental intervention may contribute to altered aspiration of oral periodontopathic bacteria into the lungs and changing inflammatory responses. Equally, periodontal diseases are associated with the longitudinal decline in spirometry lung volume. Several studies suggest a possible beneficial effect of periodontal therapy in improving lung function with a decreased frequency of exacerbations and reduced risk of adverse respiratory events and morbidity. Here, we review the current literature outlining the link between the oral cavity and pulmonary outcomes and focus on the microflora of the oral cavity, environmental and genetic factors, and preexisting conditions that can impact oral and pulmonary outcomes.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8577952/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39613153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Thyroid Gland Disease as a Comorbid Condition in COPD. 甲状腺疾病是慢性阻塞性肺病的并发症之一
IF 2 Q3 RESPIRATORY SYSTEM Pub Date : 2021-10-29 eCollection Date: 2021-01-01 DOI: 10.1155/2021/7479992
Aziz Gumus, Neslihan Ozcelik, Bilge Yilmaz Kara, Songul Ozyurt, Unal Sahin

Introduction: Chronic obstructive pulmonary disease (COPD) is one of the most common causes of morbidity and mortality worldwide. The disease is characterized by progressive airway inflammation, which not only affects the airways but also has systemic effects that are associated with comorbidities. Although comorbid conditions such as hypertension and coronary artery disease are very well-known in COPD patients, diseases of the thyroid gland have not been sufficiently studied. Therefore, thyroid diseases are not considered among the comorbid conditions of COPD. The purpose of this study was to determine the thyroid gland disease (TGD) prevalence in COPD and associated factors. Materials and Method. The study included 309 (297 (96%) male) patients. The patients were subjected to spirometry and thyroid function tests (TFT) in the stable period. The thyroid gland disease they were diagnosed with was recorded after face-to-face meetings and examining their files.

Results: The mean age of the patients who were included in the study was 65.9 ± 9.8 (40-90). Thyroid disease was determined in 68 (22%) individuals. There were hypothyroidism in 7 (2%), euthyroidism in 45 (15%), and hyperthyroidism in 16 (%5) patients. No relationship was found between the severity of airflow limitation and the prevalence of TGD.

Conclusion: Thyroid abnormalities are commonly observed in COPD. The most frequently encountered TGDs are euthyroid multinodular goiter, euthyroid sick syndrome (ESS), and toxic multinodular goiter.

导言:慢性阻塞性肺疾病(COPD)是全球最常见的发病和死亡原因之一。慢性阻塞性肺病的特征是进行性气道炎症,它不仅影响气道,还会对全身产生影响,并伴有合并症。虽然高血压和冠状动脉疾病等合并症在慢性阻塞性肺病患者中非常常见,但甲状腺疾病尚未得到充分研究。因此,甲状腺疾病并不属于慢性阻塞性肺病的合并症。本研究旨在确定慢性阻塞性肺病中甲状腺疾病(TGD)的患病率及相关因素。材料和方法。研究共纳入 309 名患者(297 名男性,占 96%)。患者在稳定期接受了肺活量测定和甲状腺功能检测(TFT)。在与患者面对面交流并查阅其档案后,记录了他们被诊断出的甲状腺疾病:研究对象的平均年龄为 65.9 ± 9.8 (40-90)岁。68人(22%)患有甲状腺疾病。其中 7 人(2%)患有甲状腺功能减退症,45 人(15%)患有甲状腺功能亢进症,16 人(5%)患有甲状腺功能亢进症。气流受限的严重程度与 TGD 的患病率之间没有关系:结论:甲状腺异常在慢性阻塞性肺病中很常见。结论:甲状腺异常在慢性阻塞性肺病中很常见,最常见的TGD是甲状腺功能亢进性多结节性甲状腺肿、甲状腺功能亢进性疾病综合征(ESS)和毒性多结节性甲状腺肿。
{"title":"Thyroid Gland Disease as a Comorbid Condition in COPD.","authors":"Aziz Gumus, Neslihan Ozcelik, Bilge Yilmaz Kara, Songul Ozyurt, Unal Sahin","doi":"10.1155/2021/7479992","DOIUrl":"10.1155/2021/7479992","url":null,"abstract":"<p><strong>Introduction: </strong>Chronic obstructive pulmonary disease (COPD) is one of the most common causes of morbidity and mortality worldwide. The disease is characterized by progressive airway inflammation, which not only affects the airways but also has systemic effects that are associated with comorbidities. Although comorbid conditions such as hypertension and coronary artery disease are very well-known in COPD patients, diseases of the thyroid gland have not been sufficiently studied. Therefore, thyroid diseases are not considered among the comorbid conditions of COPD. The purpose of this study was to determine the thyroid gland disease (TGD) prevalence in COPD and associated factors. <i>Materials and Method</i>. The study included 309 (297 (96%) male) patients. The patients were subjected to spirometry and thyroid function tests (TFT) in the stable period. The thyroid gland disease they were diagnosed with was recorded after face-to-face meetings and examining their files.</p><p><strong>Results: </strong>The mean age of the patients who were included in the study was 65.9 ± 9.8 (40-90). Thyroid disease was determined in 68 (22%) individuals. There were hypothyroidism in 7 (2%), euthyroidism in 45 (15%), and hyperthyroidism in 16 (%5) patients. No relationship was found between the severity of airflow limitation and the prevalence of TGD.</p><p><strong>Conclusion: </strong>Thyroid abnormalities are commonly observed in COPD. The most frequently encountered TGDs are euthyroid multinodular goiter, euthyroid sick syndrome (ESS), and toxic multinodular goiter.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":2.0,"publicationDate":"2021-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8570902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39597542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chest X-Ray Findings in COVID-19 Patients Presenting to Primary Care during the Peak of the First Wave of the Pandemic in Qatar: Their Association with Clinical and Laboratory Findings. 卡塔尔第一波大流行高峰期间接受初级保健的COVID-19患者的胸部x线检查结果:与临床和实验室结果的关系
IF 4.3 Q1 Medicine Pub Date : 2021-10-27 eCollection Date: 2021-01-01 DOI: 10.1155/2021/4496488
Abdelwahed Abougazia, Ahmed Alnuaimi, Amal Mahran, Tamer Ali, Ahmed Khedr, Banan Qadourah, Ahmed Shareef, Soubhi Zitouni, Servet Kahveci, Barham Alqudah, Yasser Al Yassin, Mohamed Eldesoky, Ahmed Abdelmoneim, Reda Youssef

When managing coronavirus disease 2019 (COVID-19) patients, radiological imaging complements clinical evaluation and laboratory parameters. We aimed to assess the sensitivity of chest radiography findings in detecting COVID-19, describe those findings, and assess the association of positive chest radiography findings with clinical and laboratory findings. A multicentre, cross-sectional study was conducted involving all primary health care corporation-registered patients (2485 patients) enrolled over a 1-month period during the peak of the 2020 pandemic wave in Qatar. These patients had reverse transcription-polymerase chain reaction-confirmed COVID-19 and underwent chest radiography within 72 hours of the swab test. A positive result on reverse transcription-polymerase chain reaction was the gold standard for diagnosing COVID-19. The sensitivity of chest radiography was calculated. The airspace opacities were mostly distributed in the peripheral and lower lung zones, and most of the patients had bilateral involvement. Pleural effusion was detected in some cases. The risk of having positive chest X-ray findings increased with age, Southeast Asian nationality, fever, or a history of fever and diarrhoea. Patients with cardiac disease, obesity, hypertension, diabetes, and chronic kidney disease were at a higher risk of having positive chest X-ray findings. There was a statistically significant increase in the mean serum albumin, white blood cell count, neutrophil count, and serum C-reactive protein, hepatic enzymes, and total bilirubin with an increase in the radiographic severity score.

在管理2019冠状病毒病(COVID-19)患者时,放射成像补充了临床评估和实验室参数。我们的目的是评估胸片检查结果在检测COVID-19中的敏感性,描述这些结果,并评估胸片阳性结果与临床和实验室结果的关系。在卡塔尔2020年大流行高峰期间,对所有初级卫生保健公司注册的患者(2485名患者)进行了一项多中心横断面研究,为期1个月。这些患者经逆转录聚合酶链反应确诊为COVID-19,并在拭子检测后72小时内接受了胸片检查。逆转录聚合酶链反应阳性是诊断新冠肺炎的金标准。计算胸片的灵敏度。肺空域混浊多分布于外周及肺下区,多为双侧累及。部分病例发现胸腔积液。胸片呈阳性的风险随着年龄、东南亚国籍、发热或有发热和腹泻史而增加。患有心脏病、肥胖、高血压、糖尿病和慢性肾脏疾病的患者胸部x线检查呈阳性的风险更高。平均血清白蛋白、白细胞计数、中性粒细胞计数、血清c反应蛋白、肝酶和总胆红素随着放射学严重程度评分的增加而增加,具有统计学意义。
{"title":"Chest X-Ray Findings in COVID-19 Patients Presenting to Primary Care during the Peak of the First Wave of the Pandemic in Qatar: Their Association with Clinical and Laboratory Findings.","authors":"Abdelwahed Abougazia,&nbsp;Ahmed Alnuaimi,&nbsp;Amal Mahran,&nbsp;Tamer Ali,&nbsp;Ahmed Khedr,&nbsp;Banan Qadourah,&nbsp;Ahmed Shareef,&nbsp;Soubhi Zitouni,&nbsp;Servet Kahveci,&nbsp;Barham Alqudah,&nbsp;Yasser Al Yassin,&nbsp;Mohamed Eldesoky,&nbsp;Ahmed Abdelmoneim,&nbsp;Reda Youssef","doi":"10.1155/2021/4496488","DOIUrl":"https://doi.org/10.1155/2021/4496488","url":null,"abstract":"<p><p>When managing coronavirus disease 2019 (COVID-19) patients, radiological imaging complements clinical evaluation and laboratory parameters. We aimed to assess the sensitivity of chest radiography findings in detecting COVID-19, describe those findings, and assess the association of positive chest radiography findings with clinical and laboratory findings. A multicentre, cross-sectional study was conducted involving all primary health care corporation-registered patients (2485 patients) enrolled over a 1-month period during the peak of the 2020 pandemic wave in Qatar. These patients had reverse transcription-polymerase chain reaction-confirmed COVID-19 and underwent chest radiography within 72 hours of the swab test. A positive result on reverse transcription-polymerase chain reaction was the gold standard for diagnosing COVID-19. The sensitivity of chest radiography was calculated. The airspace opacities were mostly distributed in the peripheral and lower lung zones, and most of the patients had bilateral involvement. Pleural effusion was detected in some cases. The risk of having positive chest X-ray findings increased with age, Southeast Asian nationality, fever, or a history of fever and diarrhoea. Patients with cardiac disease, obesity, hypertension, diabetes, and chronic kidney disease were at a higher risk of having positive chest X-ray findings. There was a statistically significant increase in the mean serum albumin, white blood cell count, neutrophil count, and serum C-reactive protein, hepatic enzymes, and total bilirubin with an increase in the radiographic severity score.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-10-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8553512/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39580269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 11
Analysis of SARS-CoV-2 PCR and Chest CT Findings at a Single Facility in Tokyo (Machida Municipal Hospital). 东京单一医院(町田市医院)SARS-CoV-2 PCR和胸部CT结果分析
IF 4.3 Q1 Medicine Pub Date : 2021-07-26 eCollection Date: 2021-01-01 DOI: 10.1155/2021/6680232
Taisuke Kazuyori, Akihito Sato, Yasuhiro Morimoto, Kazuyoshi Kuwano

Introduction: The SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) test is useful for diagnosing COVID-19, and the RT-PCR positive rate is an important indicator for estimating the incidence rate and number of infections. COVID-19 pneumonia is also associated with characteristic findings on chest CT, which can aid in diagnosis.

Methods: We retrospectively evaluated patient background characteristics, the number of cases, the positivity rate, and chest CT findings for positive and negative cases in 672 patients who underwent RT-PCR for suspected COVID-19 at our hospital between April 3 and August 28, 2020. In addition, we compared trends in the positive rates at approximately weekly intervals with trends in the number of new infections in Machida City, Tokyo.

Results: The study included 323 men and 349 women, with a median age of 46 years (range: 1 month-100 years). RT-PCR findings were positive in 37 cases, and the positive rate was 5.51%. Trends in the positive rate at our hospital and the number of new COVID-19 cases in the city were similar during the study period. Among patients with positive results, 15 (40.5%) had chest CT findings, and 14 had bilateral homogeneous GGOs. Among patients with negative results, 190 had chest CT findings at the time of examination, and 150 were diagnosed with bacterial pneumonia or bronchitis, with main findings consisting of consolidations and centrilobular opacities. Only 11 of these patients exhibited bilateral homogeneous GGOs.

Conclusion: Bilateral homogeneous GGOs are characteristic of COVID-19 pneumonia and may aid in the diagnosis of COVID-19.

简介:SARS-CoV-2逆转录聚合酶链反应(RT-PCR)检测对COVID-19的诊断有重要意义,RT-PCR阳性率是估计发病率和感染人数的重要指标。COVID-19肺炎还与胸部CT的特征性表现有关,这有助于诊断。方法:回顾性分析2020年4月3日至8月28日在我院接受RT-PCR检测的672例疑似COVID-19患者的患者背景特征、病例数、阳性率以及阳性和阴性病例的胸部CT表现。此外,我们比较了大约每隔一周的阳性率趋势与东京町田市新感染人数的趋势。结果:该研究包括323名男性和349名女性,中位年龄为46岁(范围:1个月-100岁)。RT-PCR阳性37例,阳性率为5.51%。在研究期间,我院的阳性率和全市新发病例数的趋势相似。在阳性结果的患者中,15例(40.5%)有胸部CT表现,14例有双侧均质性ggo。结果阴性的患者中,190例在检查时有胸部CT表现,150例诊断为细菌性肺炎或支气管炎,主要表现为实变和小叶中心混浊。这些患者中只有11例表现为双侧均质ggo。结论:双侧均质性ggo是COVID-19肺炎的特征,可能有助于COVID-19的诊断。
{"title":"Analysis of SARS-CoV-2 PCR and Chest CT Findings at a Single Facility in Tokyo (Machida Municipal Hospital).","authors":"Taisuke Kazuyori,&nbsp;Akihito Sato,&nbsp;Yasuhiro Morimoto,&nbsp;Kazuyoshi Kuwano","doi":"10.1155/2021/6680232","DOIUrl":"https://doi.org/10.1155/2021/6680232","url":null,"abstract":"<p><strong>Introduction: </strong>The SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) test is useful for diagnosing COVID-19, and the RT-PCR positive rate is an important indicator for estimating the incidence rate and number of infections. COVID-19 pneumonia is also associated with characteristic findings on chest CT, which can aid in diagnosis.</p><p><strong>Methods: </strong>We retrospectively evaluated patient background characteristics, the number of cases, the positivity rate, and chest CT findings for positive and negative cases in 672 patients who underwent RT-PCR for suspected COVID-19 at our hospital between April 3 and August 28, 2020. In addition, we compared trends in the positive rates at approximately weekly intervals with trends in the number of new infections in Machida City, Tokyo.</p><p><strong>Results: </strong>The study included 323 men and 349 women, with a median age of 46 years (range: 1 month-100 years). RT-PCR findings were positive in 37 cases, and the positive rate was 5.51%. Trends in the positive rate at our hospital and the number of new COVID-19 cases in the city were similar during the study period. Among patients with positive results, 15 (40.5%) had chest CT findings, and 14 had bilateral homogeneous GGOs. Among patients with negative results, 190 had chest CT findings at the time of examination, and 150 were diagnosed with bacterial pneumonia or bronchitis, with main findings consisting of consolidations and centrilobular opacities. Only 11 of these patients exhibited bilateral homogeneous GGOs.</p><p><strong>Conclusion: </strong>Bilateral homogeneous GGOs are characteristic of COVID-19 pneumonia and may aid in the diagnosis of COVID-19.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8324394/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39265607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
ECG Abnormalities in Patients with Acute Exacerbation of Bronchiectasis and Factors Associated with High Probability of Abnormality. 支气管扩张症急性加重期患者的心电图异常及与高异常概率相关的因素。
IF 4.3 Q1 Medicine Pub Date : 2021-07-05 eCollection Date: 2021-01-01 DOI: 10.1155/2021/6649572
Fatima Alhamed Alduihi

Background: Bronchiectasis is an important reason for morbidity and mortality according to the last records that referred to high incidence rate of disease. Cardiovascular problems are common in pulmonary diseases, in general, and it can symptom by ECG abnormalities. The objective of this study was to define the most ECG abnormalities in patients with acute exacerbation of bronchiectasis and to study the correlation between the cardiac disorder and the other risk factors of the exacerbation.

Materials and methods: A prospective single-center observational cohort study was done at Aleppo University Hospital for patients with AEB between October 2017 and September 2018. They were divided into 2 groups (normal ECG vs. abnormal). Patients with COPD, cystic fibrosis, new diagnosis of ischemic accident through the last 6 months of the study, and treatment with macrolides or fluoroquinolones through the last 3 months of the study were excluded. We study the percent of abnormalities through the AEB and the percentage of the most common abnormalities.

Results: 67 patients were included in the study (44 males and 23 females) with a mean age of 52.85 ± 21.456. ECG abnormalities were recorded in 43 patients, and it was more common in men (67.44% of cases). Advanced age and survival state had a statistical significance (p = 0.003, 0.023), respectively, between the 2 groups. Right axis deviation (RAD) is the most common abnormality (23.3%) followed by sinus tachycardia (20.9%), and it is close to T-depression (18.6%). AF was the most common arrhythmia from all recorded arrhythmias (6.98% from all cases). Positive sputum cultures were recorded in 55.8%, and the most common isolated pathogen factor was Pseudomonas aeruginosa. Recurrent pneumonia was seen in 30.2% of all patients with abnormal ECG. We find a high prevalence of ECG abnormalities in patients with Oximetry (90-95%, 39.5%), and the opportunity for abnormalities is equal in the 2 age groups (45-59 and more than 75) that reflexed the possibility of cardiac disorders in any age in patients with AEB.

Conclusions: ECG abnormalities are common in AEB, and it can happen in any age and any value of Oximetry. It needs more attention because of the prognosis of the cardiac morbidity.

背景:根据最近的记录,支气管扩张症是导致发病和死亡的一个重要原因,其发病率很高。一般来说,心血管问题在肺部疾病中很常见,它可以通过心电图异常表现出来。本研究的目的是确定支气管扩张急性加重期患者的心电图异常情况,并研究心脏疾病与其他加重风险因素之间的相关性:2017年10月至2018年9月期间,阿勒颇大学医院对AEB患者进行了一项前瞻性单中心观察性队列研究。他们被分为两组(正常心电图与异常心电图)。排除了患有慢性阻塞性肺病、囊性纤维化、研究最后 6 个月内新诊断出缺血性事故以及研究最后 3 个月内使用大环内酯类或氟喹诺酮类药物治疗的患者。我们研究了 AEB 异常的百分比以及最常见异常的百分比:研究共纳入 67 名患者(44 名男性和 23 名女性),平均年龄为(52.85 ± 21.456)岁。有 43 例患者出现心电图异常,其中男性更为常见(占 67.44%)。两组患者的高龄和生存状态分别具有统计学意义(P = 0.003,0.023)。右轴偏离(RAD)是最常见的异常(23.3%),其次是窦性心动过速(20.9%),与T抑制(18.6%)接近。在所有记录的心律失常中,房颤是最常见的心律失常(占所有病例的 6.98%)。痰培养阳性率为 55.8%,最常见的分离病原体是铜绿假单胞菌。在所有心电图异常的患者中,30.2%的患者出现了复发性肺炎。我们发现心电图异常在血氧饱和度患者中的发生率很高(90%-95%,39.5%),而且在两个年龄组(45-59 岁和 75 岁以上)中发生异常的机会相同,这反映出任何年龄段的 AEB 患者都有可能出现心脏疾病:结论:心电图异常在 AEB 中很常见,任何年龄、任何血氧饱和度值的患者都有可能出现心电图异常。由于心脏疾病的预后较差,因此需要给予更多关注。
{"title":"ECG Abnormalities in Patients with Acute Exacerbation of Bronchiectasis and Factors Associated with High Probability of Abnormality.","authors":"Fatima Alhamed Alduihi","doi":"10.1155/2021/6649572","DOIUrl":"10.1155/2021/6649572","url":null,"abstract":"<p><strong>Background: </strong>Bronchiectasis is an important reason for morbidity and mortality according to the last records that referred to high incidence rate of disease. Cardiovascular problems are common in pulmonary diseases, in general, and it can symptom by ECG abnormalities. The objective of this study was to define the most ECG abnormalities in patients with acute exacerbation of bronchiectasis and to study the correlation between the cardiac disorder and the other risk factors of the exacerbation.</p><p><strong>Materials and methods: </strong>A prospective single-center observational cohort study was done at Aleppo University Hospital for patients with AEB between October 2017 and September 2018. They were divided into 2 groups (normal ECG vs. abnormal). Patients with COPD, cystic fibrosis, new diagnosis of ischemic accident through the last 6 months of the study, and treatment with macrolides or fluoroquinolones through the last 3 months of the study were excluded. We study the percent of abnormalities through the AEB and the percentage of the most common abnormalities.</p><p><strong>Results: </strong>67 patients were included in the study (44 males and 23 females) with a mean age of 52.85 ± 21.456. ECG abnormalities were recorded in 43 patients, and it was more common in men (67.44% of cases). Advanced age and survival state had a statistical significance (<i>p</i> = 0.003, 0.023), respectively, between the 2 groups. Right axis deviation (RAD) is the most common abnormality (23.3%) followed by sinus tachycardia (20.9%), and it is close to T-depression (18.6%). AF was the most common arrhythmia from all recorded arrhythmias (6.98% from all cases). Positive sputum cultures were recorded in 55.8%, and the most common isolated pathogen factor was <i>Pseudomonas aeruginosa</i>. Recurrent pneumonia was seen in 30.2% of all patients with abnormal ECG. We find a high prevalence of ECG abnormalities in patients with Oximetry (90-95%, 39.5%), and the opportunity for abnormalities is equal in the 2 age groups (45-59 and more than 75) that reflexed the possibility of cardiac disorders in any age in patients with AEB.</p><p><strong>Conclusions: </strong>ECG abnormalities are common in AEB, and it can happen in any age and any value of Oximetry. It needs more attention because of the prognosis of the cardiac morbidity.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-07-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277499/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39265508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and Patterns of Sleep-Disordered Breathing in Indian Heart Failure Population. 印度心力衰竭人群睡眠呼吸障碍的患病率和模式。
IF 4.3 Q1 Medicine Pub Date : 2021-07-03 eCollection Date: 2021-01-01 DOI: 10.1155/2021/9978906
Sajit Kishan, Mugula Sudhakar Rao, Padmakumar Ramachandran, Tom Devasia, Jyothi Samanth

Background: Sleep-disordered breathing (SDB) is a common yet a largely underdiagnosed entity in developing countries. It is one treatable condition that is known to adversely affect the mortality and morbidity in heart failure (HF). This study is one of the first attempts aimed at studying SDB in chronic HF patients from an Indian subcontinent.

Objectives: The aim of this study was to study the prevalence, type, and characteristics of SDB in chronic HF patients and their association with HF severity and left ventricular (LV) systolic function and also to determine the relevance of SDB symptoms and screening questionnaires such as the Epworth Sleepiness Scale (ESS), Berlins questionnaire, and STOP-BANG score in predicting SDB in chronic HF patients.

Methods: We enrolled 103 chronic heart failure patients aged more than 18 years. Patients with a history of SDB and recent acute coronary syndrome within 3 months were excluded. Relevant clinical data, anthropometric measures, echocardiographic parameters, and sleep apnea questionnaires were collected, and all patients underwent the overnight type 3 sleep study.

Results: The overall prevalence of SDB in our study was high at 81.55% (84/103), with a predominant type of SDB being obstructive sleep apnea (59.2%). The occurrence of SDB was significantly associated with the male gender (p = 0.002) and higher body mass index (BMI) values (p = 0.01). SDB symptoms and questionnaires like ESS, STOP-BANG, and Berlins also did not have a significant association with the occurrence of SDB in HF patients.

Conclusions: Our study showed a high prevalence of occult SDB predominantly OSA, in chronic HF patients. We advocate routine screening for occult SDB in HF patients.

背景:在发展中国家,睡眠呼吸障碍(SDB)是一种常见但未被充分诊断的疾病。它是一种可治疗的疾病,已知会对心力衰竭(HF)的死亡率和发病率产生不利影响。本研究是印度次大陆慢性心衰患者SDB研究的首次尝试之一。目的:本研究旨在研究慢性HF患者SDB的患病率、类型、特征及其与HF严重程度和左心室收缩功能的关系,并确定SDB症状和筛选问卷(如Epworth嗜睡量表(ESS)、Berlins问卷、STOP-BANG评分)对慢性HF患者SDB的预测意义。方法:纳入103例18岁以上慢性心力衰竭患者。排除3个月内有SDB病史和近期急性冠脉综合征的患者。收集相关临床资料、人体测量、超声心动图参数和睡眠呼吸暂停问卷,所有患者均进行过夜3型睡眠研究。结果:在我们的研究中,SDB的总体患病率为81.55%(84/103),以阻塞性睡眠呼吸暂停为主要类型(59.2%)。SDB的发生与男性(p = 0.002)和较高的身体质量指数(BMI)值(p = 0.01)显著相关。SDB症状和问卷调查如ESS、STOP-BANG、Berlins与HF患者SDB的发生也无显著相关性。结论:我们的研究显示,在慢性心衰患者中,以OSA为主的隐匿性SDB患病率很高。我们提倡对心衰患者进行隐匿性SDB的常规筛查。
{"title":"Prevalence and Patterns of Sleep-Disordered Breathing in Indian Heart Failure Population.","authors":"Sajit Kishan,&nbsp;Mugula Sudhakar Rao,&nbsp;Padmakumar Ramachandran,&nbsp;Tom Devasia,&nbsp;Jyothi Samanth","doi":"10.1155/2021/9978906","DOIUrl":"https://doi.org/10.1155/2021/9978906","url":null,"abstract":"<p><strong>Background: </strong>Sleep-disordered breathing (SDB) is a common yet a largely underdiagnosed entity in developing countries. It is one treatable condition that is known to adversely affect the mortality and morbidity in heart failure (HF). This study is one of the first attempts aimed at studying SDB in chronic HF patients from an Indian subcontinent.</p><p><strong>Objectives: </strong>The aim of this study was to study the prevalence, type, and characteristics of SDB in chronic HF patients and their association with HF severity and left ventricular (LV) systolic function and also to determine the relevance of SDB symptoms and screening questionnaires such as the Epworth Sleepiness Scale (ESS), Berlins questionnaire, and STOP-BANG score in predicting SDB in chronic HF patients.</p><p><strong>Methods: </strong>We enrolled 103 chronic heart failure patients aged more than 18 years. Patients with a history of SDB and recent acute coronary syndrome within 3 months were excluded. Relevant clinical data, anthropometric measures, echocardiographic parameters, and sleep apnea questionnaires were collected, and all patients underwent the overnight type 3 sleep study.</p><p><strong>Results: </strong>The overall prevalence of SDB in our study was high at 81.55% (84/103), with a predominant type of SDB being obstructive sleep apnea (59.2%). The occurrence of SDB was significantly associated with the male gender (<i>p</i> = 0.002) and higher body mass index (BMI) values (<i>p</i> = 0.01). SDB symptoms and questionnaires like ESS, STOP-BANG, and Berlins also did not have a significant association with the occurrence of SDB in HF patients.</p><p><strong>Conclusions: </strong>Our study showed a high prevalence of occult SDB predominantly OSA, in chronic HF patients. We advocate routine screening for occult SDB in HF patients.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8275383/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39203008","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
The Impact of COVID-19 on Hospitalised COPD Exacerbations in Malta. COVID-19 对马耳他住院慢性阻塞性肺疾病恶化的影响。
IF 4.3 Q1 Medicine Pub Date : 2021-06-23 eCollection Date: 2021-01-01 DOI: 10.1155/2021/5533123
Yvette Farrugia, Bernard Paul Spiteri Meilak, Neil Grech, Rachelle Asciak, Liberato Camilleri, Stephen Montefort, Christopher Zammit

Method: Data was collected retrospectively from electronic hospital records during the periods 1st March until 10th May in 2019 and 2020.

Results: There was a marked decrease in AECOPD admissions in 2020, with a 54.2% drop in admissions (n = 119 in 2020 vs. n = 259 in 2019). There was no significant difference in patient demographics or medical comorbidities. In 2020, there was a significantly lower number of patients with AECOPD who received nebulised medications during admission (60.4% in 2020 vs. 84.9% in 2019; p ≤ 0.001). There were also significantly lower numbers of AECOPD patients admitted in 2020 who received controlled oxygen via venturi masks (69.0% in 2020 vs. 84.5% in 2019; p = 0.006). There was a significant increase in inpatient mortality in 2020 (19.3% [n = 23] and 8.4% [n = 22] for 2020 and 2019, respectively, p = 0.003). Year was found to be the best predictor of mortality outcome (p = 0.001). The lack of use of SABA pre-admission treatment (p = 0.002), active malignancy (p = 0.003), and increased length of hospital stay (p = 0.046) were also found to be predictors of mortality for AECOPD patients; however, these parameters were unchanged between 2019 and 2020 and therefore could not account for the increase in mortality.

Conclusions: There was a decrease in the number of admissions with AECOPD in 2020 during the COVID-19 pandemic, when compared to 2019. The year 2020 proved to be a significant predictor for inpatient mortality, with a significant increase in mortality in 2020. The decrease in nebuliser and controlled oxygen treatment noted in the study period did not prove to be a significant predictor of mortality when corrected for other variables. Therefore, the difference in mortality cannot be explained with certainty in this retrospective cohort study.

方法从医院电子病历中回顾性收集2019年和2020年3月1日至5月10日期间的数据:2020年AECOPD入院人数明显减少,入院人数下降了54.2%(2020年为119人,2019年为259人)。患者的人口统计学和合并症没有明显差异。2020年,入院时接受雾化治疗的AECOPD患者人数明显减少(2020年为60.4%,2019年为84.9%;P≤0.001)。2020 年入院的 AECOPD 患者中,通过文丘里面罩接受控制性供氧的人数也明显减少(2020 年为 69.0% 对比起 2019 年的 84.5%;p = 0.006)。2020 年的住院患者死亡率明显上升(2020 年和 2019 年分别为 19.3% [n = 23] 和 8.4% [n = 22],p = 0.003)。年份是预测死亡结果的最佳指标(p = 0.001)。入院前未使用SABA治疗(p = 0.002)、活动性恶性肿瘤(p = 0.003)和住院时间延长(p = 0.046)也被发现是AECOPD患者死亡率的预测因素;然而,这些参数在2019年和2020年之间没有变化,因此不能解释死亡率增加的原因:在 COVID-19 大流行期间,2020 年的 AECOPD 入院人数比 2019 年有所减少。事实证明,2020 年是住院病人死亡率的重要预测因素,2020 年的死亡率显著上升。在研究期间,雾化治疗和控制性供氧治疗的减少在校正了其他变量后,并未被证明是死亡率的重要预测因素。因此,这项回顾性队列研究无法确切解释死亡率的差异。
{"title":"The Impact of COVID-19 on Hospitalised COPD Exacerbations in Malta.","authors":"Yvette Farrugia, Bernard Paul Spiteri Meilak, Neil Grech, Rachelle Asciak, Liberato Camilleri, Stephen Montefort, Christopher Zammit","doi":"10.1155/2021/5533123","DOIUrl":"10.1155/2021/5533123","url":null,"abstract":"<p><strong>Method: </strong>Data was collected retrospectively from electronic hospital records during the periods 1st March until 10th May in 2019 and 2020.</p><p><strong>Results: </strong>There was a marked decrease in AECOPD admissions in 2020, with a 54.2% drop in admissions (<i>n</i> = 119 in 2020 vs. <i>n</i> = 259 in 2019). There was no significant difference in patient demographics or medical comorbidities. In 2020, there was a significantly lower number of patients with AECOPD who received nebulised medications during admission (60.4% in 2020 vs. 84.9% in 2019; <i>p</i> ≤ 0.001). There were also significantly lower numbers of AECOPD patients admitted in 2020 who received controlled oxygen <i>via</i> venturi masks (69.0% in 2020 vs. 84.5% in 2019; <i>p</i> = 0.006). There was a significant increase in inpatient mortality in 2020 (19.3% [<i>n</i> = 23] and 8.4% [<i>n</i> = 22] for 2020 and 2019, respectively, <i>p</i> = 0.003). Year was found to be the best predictor of mortality outcome (<i>p</i> = 0.001). The lack of use of SABA pre-admission treatment (<i>p</i> = 0.002), active malignancy (<i>p</i> = 0.003), and increased length of hospital stay (<i>p</i> = 0.046) were also found to be predictors of mortality for AECOPD patients; however, these parameters were unchanged between 2019 and 2020 and therefore could not account for the increase in mortality.</p><p><strong>Conclusions: </strong>There was a decrease in the number of admissions with AECOPD in 2020 during the COVID-19 pandemic, when compared to 2019. The year 2020 proved to be a significant predictor for inpatient mortality, with a significant increase in mortality in 2020. The decrease in nebuliser and controlled oxygen treatment noted in the study period did not prove to be a significant predictor of mortality when corrected for other variables. Therefore, the difference in mortality cannot be explained with certainty in this retrospective cohort study.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-06-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8241528/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39181417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The S100 Protein Family as Players and Therapeutic Targets in Pulmonary Diseases. S100蛋白家族在肺部疾病中的作用及治疗靶点
IF 4.3 Q1 Medicine Pub Date : 2021-06-18 eCollection Date: 2021-01-01 DOI: 10.1155/2021/5488591
Zeeshan Sattar, Alnardo Lora, Bakr Jundi, Christopher Railwah, Patrick Geraghty

The S100 protein family consists of over 20 members in humans that are involved in many intracellular and extracellular processes, including proliferation, differentiation, apoptosis, Ca2 + homeostasis, energy metabolism, inflammation, tissue repair, and migration/invasion. Although there are structural similarities between each member, they are not functionally interchangeable. The S100 proteins function both as intracellular Ca2+ sensors and as extracellular factors. Dysregulated responses of multiple members of the S100 family are observed in several diseases, including the lungs (asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and lung cancer). To this degree, extensive research was undertaken to identify their roles in pulmonary disease pathogenesis and the identification of inhibitors for several S100 family members that have progressed to clinical trials in patients for nonpulmonary conditions. This review outlines the potential role of each S100 protein in pulmonary diseases, details the possible mechanisms observed in diseases, and outlines potential therapeutic strategies for treatment.

S100蛋白家族在人类中有超过20个成员,参与许多细胞内和细胞外过程,包括增殖、分化、凋亡、Ca2 +稳态、能量代谢、炎症、组织修复和迁移/入侵。虽然每个成员之间有结构上的相似性,但它们在功能上是不可互换的。S100蛋白既作为细胞内Ca2+传感器又作为细胞外因子。多种S100家族成员的失调反应在多种疾病中被观察到,包括肺(哮喘、慢性阻塞性肺疾病、特发性肺纤维化、囊性纤维化、肺动脉高压和肺癌)。为此,开展了广泛的研究,以确定它们在肺部疾病发病机制中的作用,并确定几种S100家族成员的抑制剂,这些抑制剂已在非肺部疾病患者中进行临床试验。本文概述了每种S100蛋白在肺部疾病中的潜在作用,详细介绍了在疾病中观察到的可能机制,并概述了潜在的治疗策略。
{"title":"The S100 Protein Family as Players and Therapeutic Targets in Pulmonary Diseases.","authors":"Zeeshan Sattar,&nbsp;Alnardo Lora,&nbsp;Bakr Jundi,&nbsp;Christopher Railwah,&nbsp;Patrick Geraghty","doi":"10.1155/2021/5488591","DOIUrl":"https://doi.org/10.1155/2021/5488591","url":null,"abstract":"<p><p>The S100 protein family consists of over 20 members in humans that are involved in many intracellular and extracellular processes, including proliferation, differentiation, apoptosis, Ca<sub>2</sub> <sup>+</sup> homeostasis, energy metabolism, inflammation, tissue repair, and migration/invasion. Although there are structural similarities between each member, they are not functionally interchangeable. The S100 proteins function both as intracellular Ca<sup>2+</sup> sensors and as extracellular factors. Dysregulated responses of multiple members of the S100 family are observed in several diseases, including the lungs (asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, cystic fibrosis, pulmonary hypertension, and lung cancer). To this degree, extensive research was undertaken to identify their roles in pulmonary disease pathogenesis and the identification of inhibitors for several S100 family members that have progressed to clinical trials in patients for nonpulmonary conditions. This review outlines the potential role of each S100 protein in pulmonary diseases, details the possible mechanisms observed in diseases, and outlines potential therapeutic strategies for treatment.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8214497/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39166296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
A Machine Learning Approach to the Interpretation of Cardiopulmonary Exercise Tests: Development and Validation. 机器学习方法对心肺运动测试的解释:开发和验证。
IF 4.3 Q1 Medicine Pub Date : 2021-05-31 eCollection Date: 2021-01-01 DOI: 10.1155/2021/5516248
Or Inbar, Omri Inbar, Ronen Reuveny, Michael J Segel, Hayit Greenspan, Mickey Scheinowitz

Objective: At present, there is no consensus on the best strategy for interpreting the cardiopulmonary exercise test's (CPET) results. This study is aimed at assessing the potential of using computer-aided algorithms to evaluate CPET data for identifying chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD).

Methods: Data from 234 CPET files from the Pulmonary Institute, at Sheba Medical Center, and the Givat-Washington College, both in Israel, were selected for this study. The selected CPET files included patients with confirmed primary CHF (n = 73), COPD (n = 75), and healthy subjects (n = 86). Of the 234 CPETs, 150 (50 in each group) tests were used for the support vector machine (SVM) learning stage, and the remaining 84 tests were used for the model validation. The performance of the SVM interpretive module was assessed by comparing its interpretation output with the conventional clinical diagnosis using distribution analysis.

Results: The disease classification results show that the overall predictive power of the proposed interpretive model ranged from 96% to 100%, indicating very high predictive power. Furthermore, the sensitivity, specificity, and overall precision of the proposed interpretive module were 99%, 99%, and 99%, respectively.

Conclusions: The proposed new computer-aided CPET interpretive module was found to be highly sensitive and specific in classifying patients with CHF or COPD, or healthy. Comparable modules may well be applied to additional and larger populations (pathologies and exercise limitations), thereby making this tool powerful and clinically applicable.

目的:目前,对于解释心肺运动试验(CPET)结果的最佳策略尚无共识。本研究旨在评估使用计算机辅助算法评估CPET数据识别慢性心力衰竭(CHF)和慢性阻塞性肺疾病(COPD)的潜力。方法:选择来自以色列示巴医学中心肺科研究所和吉瓦特-华盛顿学院的234份CPET文件的数据进行研究。所选择的CPET文件包括确诊的原发性CHF (n = 73)、COPD (n = 75)和健康受试者(n = 86)。在234个cpet中,150个(每组50个)测试用于支持向量机(SVM)学习阶段,其余84个测试用于模型验证。通过分布分析将SVM解释模块的解释输出与常规临床诊断结果进行比较,评价SVM解释模块的性能。结果:疾病分类结果表明,所提出的解释模型的总体预测能力在96% ~ 100%之间,具有很高的预测能力。此外,所提出的解释模块的灵敏度、特异性和总体精度分别为99%、99%和99%。结论:提出的新的计算机辅助CPET解释模块在对CHF、COPD或健康患者进行分类时具有高度的敏感性和特异性。可比较的模块可以很好地应用于更多和更大的人群(病理和运动限制),从而使该工具功能强大且临床上适用。
{"title":"A Machine Learning Approach to the Interpretation of Cardiopulmonary Exercise Tests: Development and Validation.","authors":"Or Inbar,&nbsp;Omri Inbar,&nbsp;Ronen Reuveny,&nbsp;Michael J Segel,&nbsp;Hayit Greenspan,&nbsp;Mickey Scheinowitz","doi":"10.1155/2021/5516248","DOIUrl":"https://doi.org/10.1155/2021/5516248","url":null,"abstract":"<p><strong>Objective: </strong>At present, there is no consensus on the best strategy for interpreting the cardiopulmonary exercise test's (CPET) results. This study is aimed at assessing the potential of using computer-aided algorithms to evaluate CPET data for identifying chronic heart failure (CHF) and chronic obstructive pulmonary disease (COPD).</p><p><strong>Methods: </strong>Data from 234 CPET files from the Pulmonary Institute, at Sheba Medical Center, and the Givat-Washington College, both in Israel, were selected for this study. The selected CPET files included patients with confirmed primary CHF (<i>n</i> = 73), COPD (<i>n</i> = 75), and healthy subjects (<i>n</i> = 86). Of the 234 CPETs, 150 (50 in each group) tests were used for the support vector machine (SVM) learning stage, and the remaining 84 tests were used for the model validation. The performance of the SVM interpretive module was assessed by comparing its interpretation output with the conventional clinical diagnosis using distribution analysis.</p><p><strong>Results: </strong>The disease classification results show that the overall predictive power of the proposed interpretive model ranged from 96% to 100%, indicating very high predictive power. Furthermore, the sensitivity, specificity, and overall precision of the proposed interpretive module were 99%, 99%, and 99%, respectively.</p><p><strong>Conclusions: </strong>The proposed new computer-aided CPET interpretive module was found to be highly sensitive and specific in classifying patients with CHF or COPD, or healthy. Comparable modules may well be applied to additional and larger populations (pathologies and exercise limitations), thereby making this tool powerful and clinically applicable.</p>","PeriodicalId":46434,"journal":{"name":"Pulmonary Medicine","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2021-05-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8188599/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39029531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 10
期刊
Pulmonary Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1